A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder

Study Identifier:
382-201-00034
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information:

Study Details

Medical Condition
  • Anxiety
Study Drug
  • Drug: SEP-363856
Date
Oct 2026 - May 2029
Phase 1/2
Phase 2/3
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information

Protocol Summary

This is a global, Phase 3, multicenter, open-label extension trial designed to evaluate the long-term safety, tolerability and efficacy of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult participants with generalized anxiety disorder (GAD) over a treatment period of 26 weeks.

Study Locations

Location
Status
Location
Clinical Neuroscience Solutions, LLC
Jacksonville, Florida, United States, 32256
Status
Recruiting
Location
Clinical Neuroscience Solutions Inc. (CNS) - Orlando
Orlando, Florida, United States, 32801
Status
Recruiting
Location
Basil Clinical
Jamaica, New York, United States, 11413
Status
Recruiting
Location
Manhattan Behavioral Medicine PLLC
New York, New York, United States, 10036
Status
Recruiting
© 2025 Otsuka America Pharmaceutical,
Inc All rights reserved.

July 2025 01US25EUC0279